Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Basel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting, standing, walking and maintained the ability to swallow following 12 months of treatment.  “Tre...
Source: Roche Media News - January 25, 2022 Category: Pharmaceuticals Source Type: news

Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Basel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting, standing, walking and maintained the ability to swallow following 12 months of treatment.  “Tre...
Source: Roche Investor Update - January 25, 2022 Category: Pharmaceuticals Source Type: news

Giving Cash to Low-Income Mothers Linked to Increased Brain Activity in Their Babies, Study Suggests
New research suggests giving extra cash to low-income mothers can change their infants’ brain development. Brain measurements at age 1 showed faster activity in key brain regions in infants whose low-income families received $300-plus monthly for a year, compared with those who got $20 each month, U.S. researchers reported Monday. The same type of brain activity has been linked in older children to learning skills and other development, although it’s unclear whether the differences found will persist or influence the infants’ future. The researchers are investigating whether the payments led to better nut...
Source: TIME: Science - January 25, 2022 Category: Science Authors: Lindsey Tanner/AP Tags: Uncategorized overnight Research wire Source Type: news

Darling buds: how best friends keep us healthy and happy
Strong social networks have been shown to improve wellbeing, but what are the extra perks of having a really close friend? And why are women more likely to have one?“We met when we were five. I don’t know how I would have managed without her.” As children, Barbara Kastelein, from Ashford in Kent, and her best friend, nicknamed “Tulip”, both had alcoholic fathers. Their friendship was an escape from unhappy homes.The best friends are now both 55 and their relationship is as solid as ever. Barbara says they are more like sisters – and still there for each other during tough times. When Bar...
Source: Guardian Unlimited Science - January 22, 2022 Category: Science Authors: Katherine Latham Tags: Psychology Friendship Neuroscience Loneliness Society Life and style Source Type: news

TRPV1 and Migraines
Conclusion-the present findings indicate that insulin may activate TRPV1 receptors in the trigeminovascular system. Modified TRPV1 receptor function induced by insulin may also increase the sensitivity of both neural and vascular TRPV1 receptor for its agonists. Our data may provide a pathophysiological basis for the increased incidence of migraine in patients with hyperinsulin levels. (Source: Neuromics)
Source: Neuromics - January 21, 2022 Category: Neuroscience Source Type: news

UCSF Aims To Re-Think Neuroscience Research With Its New Building
The University of California San Francisco is attempting to re-think how basic and clinical neuroscience research and care are done with its newly opened Joan and Sanford Weill Neurosciences Building. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 20, 2022 Category: Pharmaceuticals Authors: Gabriel A. Silva, Contributor Tags: Science /science Innovation /innovation Healthcare /healthcare Source Type: news

Elon Musk ’s brain chip firm Neuralink lines up clinical trials in humans
Implants that Musk says could allow paralysed people to walk already tested on a macaque and a pigThe billionaire entrepreneur Elon Musk ’s brain chip startup is preparing to launch clinical trials in humans.Musk, who co-founded Neuralink in 2016, haspromised that the technology “will enable someone with paralysis to use a smartphone with their mind faster than someone using thumbs”.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - January 20, 2022 Category: Science Authors: Rupert Neate Wealth correspondent Tags: Elon Musk Artificial intelligence (AI) Neuroscience Technology Business Source Type: news

Pandemic Anxiety Is Fueling OCD Symptoms —Even for People Without the Disorder
Rosalyn (not her real name) had no idea what she intended to do with the three boxes of spaghetti she had just dumped into her shopping cart. She didn’t want them—she certainly didn’t need them—but never mind, she had to buy them. And the spaghetti boxes weren’t the only unwanted items she picked up in the grocery store that day during the first year of the COVID-19 pandemic. If she so much as grazed one item while she was reaching for another, into the shopping cart it went. “Everything my hand touched I had to buy,” she said. “I didn’t feel I had a choice. There was t...
Source: TIME: Health - January 20, 2022 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Researchers Train Goldfish to “Drive”
The Scientist spoke with cognitive neuroscientist Ronen Segev about how he taught goldfish to maneuver a moveable tank over land toward a visual target. (Source: The Scientist)
Source: The Scientist - January 12, 2022 Category: Science Tags: News & Opinion Source Type: news

Why can ’t we stop scrolling or eating Haribo? Blame the lizard brain | Eli Goldstone
My life is a constant struggle against the primitive part of my brain – and the forces designed to exploit itI experience frequent, urgent cravings for very specific things and act on them immediately. As soon as I open my eyes I often know exactly what I want: to wear a particular little outfit, buy a sandwich of a certain heft and filling fromthis shop inthis postcode, eat it (for instance) on a bench under a tree. It ’s a shame that the place in me capable of conjuring these whims also regularly churns out other, much more boring urges, and occasionally dangerous ones too. My brain is a constant game of Hung...
Source: Guardian Unlimited Science - January 9, 2022 Category: Science Authors: Eli Goldstone Tags: Psychology World news Science Neuroscience Source Type: news

‘We see what’s happening in their brain’: inside the ToddlerLab
At pioneering facility in London, researchers use wearable tech to see how toddlers ’ brains developWith her Mickey Mouse backpack, coloured Duplo blocks and disarmingly cute smile, Serena could be any young child constructing a toy house for an imaginary character – were it not for the wires and nodules sticking out of her head. But Serena is a pint-sized pioneer at the cutting edge of research into the enduring mystery of what makes toddlers tick. She is among the first children to be studied at the world’s first dedicated ToddlerLab – a multimillion-p ound effort to get inside the heads of toddle...
Source: Guardian Unlimited Science - January 7, 2022 Category: Science Authors: Linda Geddes Science correspondent Tags: Children Neuroscience Psychology Early years education Source Type: news

Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States
NEW BRUNSWICK, N.J., January 6, 2022 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions. The study was sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson and conducted in partnership with the Department of Science-Aetion, Inc, and the Division...
Source: Johnson and Johnson - January 6, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

The Influence of Rare Cells in the Nervous System
Sebastian Lewandowski and Philip Hasel will discuss using single-cell techniques to understand the role of rare cell subtypes in neuroinflammation and neurodegeneration. (Source: The Scientist)
Source: The Scientist - January 6, 2022 Category: Science Tags: Sponsored Webinars Source Type: news

More than a feeling: why our emotions are crucial to the way we think | Leonard Mlodinow
Contrary to what Charles Darwin once argued, emotions enhance our process of reasoning and aid decision-makingCharles Darwin created the most successful theory in the history of biology: the theory of evolution. He was also responsible for another grand theory: the theory of emotion, which dominated his field for more than a century. That theory was dead wrong.The most important tenet of his theory was that the mind consists of two competing forces, the rational and the emotional. He believed emotions played a constructive role in the lives of non-human animals, but in humans emotions were a vestige whose usefulness had be...
Source: Guardian Unlimited Science - January 5, 2022 Category: Science Authors: Leonard Mlodinow Tags: Neuroscience Psychology Biology Charles Darwin Source Type: news

Why is it so hard to lose that festive weight – and keep it off? – podcast
New year resolutions often include eating more healthily, doing exercise and trying to shift some of the extra weight put on over Christmas. Yet research suggests the vast majority of people who do lose weight ultimately end up putting nearly all of it back on. So why is it so difficult? Madeleine Finlay speaks to health journalist and ex-neuroscientist David Cox on the science of metabolism, and what it means for our healthArchive: Fox 8 News, News4JAXContinue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - January 4, 2022 Category: Science Authors: Presented by Madeleine Finlay with David Cox, produced by Anand Jagatia, sound design by Rudi Zygadlo Tags: Science Health Diets and dieting Source Type: news

Sports post-concussion syndrome (PCS) model in Drosophila melanogaster - English EA, Chazot PL.
BACKGROUND: Scientific and societal interest is growing in understanding links between sports concussion and neurodegeneration. When multiple symptoms, such as memory loss, anxiety and headaches, persist after head impact(s), this is defined as post-concus... (Source: SafetyLit)
Source: SafetyLit - January 3, 2022 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

About IBA Lifesciences
IBA Lifesciences'proprietary Strep-tag ® technology exploits one of the strongest non-covalent interactions in nature: the interaction of biotin and streptavidin. The system is based on the highly selective and easily controllable interaction between the synthetic Strep-tag®II peptide and the specially engineered streptavidin, called S trep-Tactin®, which is one of the most stable proteins known. The Strep-tag®II binds specifically to the engineered streptavidins, Strep-Tactin® and Strep-Tactin®XT, by occupying the binding pocket of the natural ligand biotin. Hence, the interaction is easily reversi...
Source: Neuromics - December 31, 2021 Category: Neuroscience Source Type: news

Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
NEW BRUNSWICK, N.J., December 30, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced new preliminary results from the South African Phase 3b Sisonke study which showed that a homologous (same vaccine) booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S) demonstrated 85 percent effectiveness against COVID-19-related hospitalization. The study, conducted by the South African Medical Research Council (SAMRC), showed that the Johnson & Johnson booster reduced the risk of hospitalization from COVID-19 among healthcare workers in South Africa after Omicron became the dominant var...
Source: Johnson and Johnson - December 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Our Favorite Neuroscience Stories of 2021
From a Nobel prize and photosynthesis-powered brains to neurodegeneration research and controversy over a new Alzheimer ’s drug, a look back at some of the biggest brain-related developments of the... (Source: The Scientist)
Source: The Scientist - December 29, 2021 Category: Science Tags: News & Opinion Source Type: news

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
RARITAN, N.J., December 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is an investigational, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3.“Despite all the gains that have been made in treating multiple myeloma, the unmet need still remains very high. Our relentless pursuit of tre...
Source: Johnson and Johnson - December 29, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news

Synthetic Alcohol Promises to Make Drinking Safer. But Experts Are Wary
Our ancestors started drinking booze millions of years ago, and we never stopped. Alcohol is embedded in nearly every culture in the world as a social lubricant, marker of taste and cornerstone of celebrations. If companies tried to bring it to market for the first time today, however, U.S. regulators would almost certainly forbid it. More than 200 health conditions—from cancer to dementia to cirrhosis— are linked to alcohol; it contributes to 3 million deaths globally each year, many via auto accidents and suicides; and in the U.S. alone, more than 14 million people struggle with alcohol-use disorder. It&rsquo...
Source: TIME: Health - December 28, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease w...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Dr. Andrew Boucher joins Semmes Murphey Clinic
Semmes Murphey Clinic has expanded the team with the addition of Dr. Andrew Boucher, who joined July 15. Dr. Boucher (pronounced Boo-shay), is a neurosurgeon with a special interest in neurosurgical oncology and a heart for all things Memphis. He also treats patients with back and/or neck pain due to common spinal disorders such as degenerative arthritis, cervical or lumbar stenosis, and herniated discs. Dr. Boucher graduated from the University of Tennessee Health Science Center and completed… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 20, 2021 Category: Pharmaceuticals Authors: Semmes Murphey Clinic Source Type: news

Non-pro athletes may also be at increased risk for CTE, neuroscientist says
NPR's Sacha Pfeiffer speaks with a man who is concerned about CTE, and with neuroscientist Bob Stern, who explains why more cases of CTE may emerge decades after plastic helmets became commonplace. (Source: NPR Health and Science)
Source: NPR Health and Science - December 19, 2021 Category: Consumer Health News Source Type: news

2021 reflections: In an amazing year of achievements, nothing topped the return to campus
As we approach the end of December, it ’s a natural time to look back at the year that was. In 2021, UCLA welcomed students, faculty, staff, alumni and visitors back to our home in Westwood, though of course it wasn’t exactly the way things had been.Different from pre-pandemic times: Masks remain present. Better (much better): UCLA officially opened the Black Bruin Resource Center.Even with all the changes, UCLA persisted as a force for public good, guided by our mission of teaching, research and service. In the past year,  professors continued helping us better understand our world with their research, st...
Source: UCLA Newsroom: Health Sciences - December 17, 2021 Category: Universities & Medical Training Source Type: news

From blood clots to infected neurons, how COVID threatens the brain
The virus that causes COVID-19 can cause strokes, inflammation, oxygen deprivation and infection in the brain. And each of these may lead to long term neurological problems. (Image credit: Kateryna Kon/Science Source) (Source: NPR Health and Science)
Source: NPR Health and Science - December 16, 2021 Category: Consumer Health News Authors: Jon Hamilton Source Type: news

Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
NEW BRUNSWICK, N.J., December 15, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company’s COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a ‘mix and match’ booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting). “We are pleased wi...
Source: Johnson and Johnson - December 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Rocket Scientists and Neurosurgeons: Who's Smarter? Rocket Scientists and Neurosurgeons: Who's Smarter?
The basis for the age-old phrases"it's not brain surgery" and"it's not rocket science" is put to the test in this intelligence study reviewed by Dr F. Perry Wilson.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2021 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news

Brain surgeons and rocket scientists no brighter than the rest of us, study finds
Data from 329 aerospace engineers and 72 neurosurgeons suggests they are not necessarily cleverer than general populationIt may not be rocket science, but researchers have found aerospace engineers and brain surgeons are not necessarily brighter than the general population.Researchers examined data from an international cohort of 329 aerospace engineers and 72 neurosurgeons who completed 12 tasks online usingthe Great British Intelligence Test (GBIT) from theCognitron platform, as well as answering questions around their age, sex and levels of experience in their speciality.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - December 13, 2021 Category: Science Authors: Nicola Davis Tags: Neuroscience Engineering Aerospace industry Doctors Technology Health Source Type: news

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the R...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy administered as a single infusion, in the treatment of patients with relapsed and/or refractory multiple myeloma. The data, featured as an oral presentation at the American Society of Hematology (ASH) 2021 Annual Meeting (Abstract #549) and selected as part of the Hi...
Source: Johnson and Johnson - December 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC)...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Clinical and Real-World Data Support Use of DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone (Rd). Updated data from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients were presented at the American Society of Hematology (ASH) 2021 Annual Meeting. Data from the GRIFFIN study will also b...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from two studies evaluating the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) as a potential fixed-duration treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These data were both featured today during the American Society of Hematology (ASH) 2021 Annual Meeting. New secondary endpoint data from the Phase 3 GLOW study (NCT03462719) showed that fixed-duration treatment with I+V resulted in undetecta...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Q & A: Dr. Thomas Rando on preventing age-related diseases and turning discoveries into cures
For Dr. Thomas Rando, the path to becoming a physician-scientist began with something that hedidn ’t learn in high school biology.After one class that touched on the connections between neurons and muscle fibers, Rando took it upon to himself to find all the information he could about how cells communicate through electrical signals.Soon, he began pursuing that interest at Harvard University, where he completed his undergraduate work, a doctorate in cell and developmental biology and his medical degree.Rando joined the neurology faculty at the Stanford University School of Medicine in 1995.There, he founded a clinic ...
Source: UCLA Newsroom: Health Sciences - December 10, 2021 Category: Universities & Medical Training Source Type: news

World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster
NEW BRUNSWICK, N.J., December 9, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the interim recommendation by the Strategic Advisory Group of Experts on Immunization (SAGE) for the World Health Organization (WHO) supporting the use of the Johnson & Johnson COVID-19 vaccine as a booster shot in persons aged 18 years and above. The WHO recommend the booster shot should be administered two to six months after the primary vaccination. SAGE advises WHO on global vaccine and immunization policies, and its recommendations provide guidance on the use of vaccines supplied through the COVAX Facility...
Source: Johnson and Johnson - December 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Nii A. Addy named Albert E. Kent Professor of Psychiatry
Yale neuroscientist Nii A. Addy studies the neurobiology of reinforcement learning and motivational control in the context of substance use and mood disorders. (Source: Yale Science and Health News)
Source: Yale Science and Health News - December 8, 2021 Category: Universities & Medical Training Source Type: news

NIDCR's Winter 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Winter 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NIDCR News Science Advances   NIDCR News NIDCR Major Announcement: Save the Date! Mark your calendar for Tuesday, December 21, at 1pm for a major webcast announcement from NIDCR. Look for log-in instructions, coming in a separate NIDCR email next week. Jennifer Webster-Cyriaque Joins NIDCR as Deputy Director NIDCR welcomed Jennifer Webster...
Source: NIDCR Science News - December 8, 2021 Category: Dentistry Source Type: news

Herpes Kidnaps Proteins to Take Up Residence in the Nervous System
The herpes virus hitches a ride to the nuclei of neurons from a surprising source. (Source: The Scientist)
Source: The Scientist - December 6, 2021 Category: Science Tags: Sponsored Article Source Type: news

Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
NEW BRUNSWICK, N.J., DECEMBER 5, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match...
Source: Johnson and Johnson - December 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Texas A&M, Wave Neuroscience partner on PTSD trial
Texas A&M University Health Science Center and Wave Neuroscience have starte...Read more on AuntMinnie.com (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 3, 2021 Category: Radiology Source Type: news

Is TikTok giving people Tourette ’s Syndrome?
Clinicians around the world have noticed an increase in young adults, often women, developing ‘tic-like behaviours’ – sudden movements or vocalisations similar to what’s seen in Tourette Syndrome. Except these tics come on much later in life, and escalate more rapidly. Some have blamed the recent rise on social media – but the reality is much more complicated.Madeleine Finlay talks to Guardian reporter Sirin Kale and research psychologist Dr Seonaid Anderson about the young people experiencing this debilitating disorder, and what can be done about it.Archive: NewsNation; TikTokContinue reading...
Source: Guardian Unlimited Science - December 2, 2021 Category: Science Authors: Presented by Madeleine Finlay, produced by Anand Jagatia, sound design by Axel Kacouti é Tags: Science Neuroscience Mental health Social media Source Type: news

The Science Behind How Roundworms Spit
By viewing countless hours of expectorating worms, researchers discover a unique way in which neurons control the movement of muscles. (Source: The Scientist)
Source: The Scientist - December 1, 2021 Category: Science Tags: Notebook Magazine Issue Source Type: news

Infographic: How C. elegans Transmit Stress Signals to Offspring
Neurons stressed with chemicals produce Wnt, which in turn triggers changes in the germline. (Source: The Scientist)
Source: The Scientist - December 1, 2021 Category: Science Tags: Infographics Magazine Issue Source Type: news

Janssen Seeks Approval of IMBRUVICA ®(ibrutinib) in a Fixed-Duration Regimen for Patients with Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 30 November 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new treatment option for IMBRUVICA® (ibrutinib) as a fixed-duration combination with venetoclax (I+V) for adult patients with previously untreated chronic lymphocytic leukaemia (CLL)."Ibrutinib was the first approved Bruton’s tyrosine kinase inhibitor and over the past seven years has become a key treatment for CLL and some other B-cell malignancies, treating more than 250,000 pati...
Source: Johnson and Johnson - November 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Studying Diabetic Retinopathy?
Check out How Neuromic's Tools Are UsedThe authors used four of Neuromics to complete this study-Sulodexide reduces glucose induced senescence in human retinal endothelial cellsA. Gericke, K. Suminska-Jasi ńska& A. Br ęborowicz Scientific Reports volume 11, Article number: 11532 (2021) Cite this article.Material and MethodsExperiments were performed on HREC (#HEC09, Neuromics, Edina, MN, USA) in in vitro culture. Cells were seeded in 75 cm2 culture flasks coated with AlphaBioCoat Solution (#AC00, Neuromics, Edina, MN, USA) and were grown in Endo Growth Medium (EKG001, Neuromics, Edina, MN, USA) supplemented with feta...
Source: Neuromics - November 24, 2021 Category: Neuroscience Tags: Cell Detachment Diabetic retinopathy Human Endothelial Cells Human Retinal Microvascular Endothelial Cells Hyperglycemia Source Type: news

Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older
Toronto ON, 24 November 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved its single-shot COVID-19 vaccine to prevent COVID-19 in individuals 18 years of age and older. This decision was based on scientific evidence, including initial data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination. “We are delighted by Health Canada’s decision to approve the Johnson & Jo...
Source: Johnson and Johnson - November 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

I have ADHD and was scared of psychedelics. Then I found myself eating magic truffles ... | Deborah Frances-White
The safe, repetitive domesticity of lockdown made me face my demons and seek therapy, while also making me hungry for sensation and risk. So I set off for a retreat in AmsterdamIf you had asked me pre-pandemic if I would ever touch psychedelics, I would have said absolutely not. The speed of my brain is literally my only skill. As a standup comedian and podcaster, I can walk out on stage with absolutely nothing in my head and riff with an audience for an hour if I need to – which I know seems like a superpower to others – while ordinary powers, such as the ability to do my laundry every week, elude me.I was rec...
Source: Guardian Unlimited Science - November 23, 2021 Category: Science Authors: Deborah Frances-White Tags: Drugs Mental health Science Society Source Type: news

Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drug
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer ’s drug experienced brain bleeding or swelling, though many cases were asymptomatic. (Source: NYT Health)
Source: NYT Health - November 22, 2021 Category: Consumer Health News Authors: Pam Belluck Tags: your-feed-science Drugs (Pharmaceuticals) Clinical Trials Aduhelm (Drug) Alzheimer ' s Disease Labeling and Labels (Product) Brain Elderly Deaths (Fatalities) Biogen Inc Food and Drug Administration JAMA Neurology (Journal) RBC Source Type: news